| MET |
Report |
Adjusted EPS |
BEAT |
pred ~$2.23 vs. cons $2.17 |
MEDIUM |
| MET |
Report |
Pre-tax variable investment income (VII) |
IN-LINE |
pred ~$245M vs. cons $245M |
HIGH |
| MET |
Report |
Group Benefits adjusted earnings |
BEAT |
pred ~$415M vs. cons $395M |
MEDIUM |
| MET |
Guide |
Full-year pre-tax VII |
BETTER |
guide ~$1.60B vs. cons $1.55B (FY2026) |
MEDIUM |
| MET |
Guide |
Full-year adjusted EPS growth |
BETTER |
guide ~11% vs. cons 10% (FY2026) |
MEDIUM |
| MET |
Guide |
RIS adjusted earnings |
UNCHANGED |
guide ~$1.70B vs. cons $1.70B (FY2026) |
MEDIUM |
| MET |
Guide |
MIM adjusted earnings |
UNCHANGED |
guide ~$260M vs. cons $260M (FY2026) |
MEDIUM |
| MET |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| MET |
Return |
5-day cumulative residual |
+1.0% (STABILIZE) |
A modest EPS beat of ~$2.23 versus $2.17 and VII near ~$245M should support an initial positive reaction, but retained FY2026 VII guidance of ~$1.60B versus ~$1.55B consensus is a reaffirmation rather than a material raise; limited out-period estimate upside should leave the 5-day residual near +1.0% after a +1.8% day-1 move. |
MEDIUM |